Synthesis and SAR of 7-substituted 2-nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines as novel antileishmanial agents

Show simple item record

dc.contributor.author O'Connor, Patrick en
dc.contributor.author Marshall, AJ en
dc.contributor.author Denny, William en
dc.contributor.author Yardley, V en
dc.contributor.author Maes, L en
dc.contributor.author Chatelain, E en
dc.contributor.author Thompson, Andrew en
dc.coverage.spatial Caen, France en
dc.date.accessioned 2018-10-11T22:07:50Z en
dc.date.issued 2016-07-06 en
dc.identifier.uri http://hdl.handle.net/2292/41055 en
dc.description.abstract (See P157 in Book of Abstracts above). Leishmaniasis is a disease which infects approximately 12 million people globally, and kills 20 to 50 thousand people annually. The disease presents in both ‘cutaneous’ and ‘visceral’ forms with the cutaneous form manifesting as disfiguring skin ulcerations, and the visceral form as a fever, low red blood cell count, enlarged spleen and liver. The disease is caused by infection with any one of over twenty protozoal parasites, of the genus Leishmania, which are transmitted from person to person occurs through a sand fly insect vector. The novel 7-substituted oxazine class exemplified by 3 and 4 were initially explored as part of an anti-tuberculosis drug development program involving the ACSRC and TB-Alliance. Later phenotypic screening of the oxazines by DNDi led to the discovery of their potent activity against Leishmania donovani. In an effort to improve solubility and safety while maintaining high VL activity over 140 phenyl, and linker group derivatives were synthesised. The most promising leads 36938 and 36940 which were synthesised in enantiopure form are being further evaluated as backup clinical candidates to DNDi’s antileishmaniasis preclinical lead VL-2098. en
dc.relation.ispartof 52nd International Conference on Medicinal Chemistry en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.title Synthesis and SAR of 7-substituted 2-nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines as novel antileishmanial agents en
dc.type Conference Poster en
dc.rights.holder Copyright: The authors en
pubs.author-url http://www.efmc.info/data/1468418904RICT16-BookAbstracts-Web-july7bis.pdf en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.elements-id 535456 en
pubs.org-id Medical and Health Sciences en
pubs.org-id Medical Sciences en
pubs.org-id Auckland Cancer Research en
pubs.org-id Science en
pubs.org-id Science Research en
pubs.org-id Maurice Wilkins Centre (2010-2014) en
pubs.record-created-at-source-date 2016-07-12 en


Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics